National Kidney Foundation invests in health tech company Revalia Bio
Click Here to Manage Email Alerts
Key takeaways:
- The Revalia Bio platform involves reviving human organs donated for research.
- The company uses advanced perfusion methods to enable organs to function outside the body.
The National Kidney Foundation Innovation Fund has invested in health technology company Revalia Bio, according to a press release.
“This investment serves as an important catalyst for advancing how new therapies are developed and delivered,” Kevin Longino, CEO of the NKF and kidney transplant recipient, said in the release. “Revalia Bio’s approach will accelerate the integration of innovative treatments for kidney disease by leveraging human organ data in a way that was previously unavailable. This will be critical in helping us gain better insight into [chronic kidney disease] CKD and ensure that health care providers have the tools they need to bring more therapies to patients faster.”
The Revalia Bio platform involves reviving human organs donated for research. The company uses advanced perfusion methods to recover organs and enable organs to function outside the body, allowing researchers to collect key data on organs in a near-living state.
Combined with advances in AI, the company intends to leverage its technology to create a more efficient drug development process and personalize kidney care for patients.
“Our mission at Revalia Bio is to transform the loss of one patient in the future of personalized care through organ donation for groundbreaking research,” Greg Tietjen, CEO of Revalia Bio, said in the release. “With the support of the National Kidney Foundation’s Innovation Fund, we are closer than ever to realizing that mission. Together, we can make a real difference in the lives of patients with kidney disease while also honoring the profound legacy of those that have unfortunately lost their fight with kidney disease.”
Reference:
National Kidney Foundation Innovation Fund invests in Revalia Bio to advance innovative kidney disease therapeutics. https://www.kidney.org/press-room/national-kidney-foundation-innovation-fund-invests-revalia-bio-to-advance-innovative. Published Oct. 17, 2024. Accessed Oct. 18, 2024.
Click Here to Manage Email Alerts